Orforglipron

Orforglipron (Foundayo) is the first oral non-peptide GLP-1 receptor agonist approved for obesity. FDA approved it on April 1, 2026, under the National Priority Voucher program, 50 days after filing and 294 days ahead of its PDUFA date. This makes it the fastest-approved GLP-1 agonist to date.

The mechanism is distinct from peptide GLP-1 agonists. Orforglipron produces a Gs-biased signaling profile with greater cyclic AMP signaling relative to beta-arrestin recruitment, which may confer lower receptor desensitization than full agonists. It binds within a transmembrane pocket formed by TM1, TM2, TM3, TM7, and extracellular loop 2, distinct from the native peptide-binding domain. As a non-peptide small molecule, orforglipron does not elicit an immune or antibody response as peptide GLP-1 agonists can.

The ATTAIN-1 trial (N=3,127, 72 weeks) is the pivotal efficacy study in obesity without diabetes. Percent body-weight change from baseline was 7.5% (6 mg), 8.4% (12 mg), and 11.2% (36 mg) versus 2.1% placebo (all P<0.001). At the 36 mg dose, 54.6% achieved at least 10% weight loss, 36.0% achieved at least 15%, and 18.4% achieved at least 20%, versus 12.9%, 5.9%, and 2.8% with placebo. Significant improvements were also seen in waist circumference, systolic blood pressure, triglycerides, and non-HDL cholesterol.

ATTAIN-2 (N=1,613, 72 weeks) tested orforglipron in adults with obesity and type 2 diabetes. Percent body-weight change was 5.1% (6 mg), 7.0% (12 mg), and 9.6% (36 mg) versus 2.5% placebo (all P<0.0001). HbA1c and weight decreased by an average of 1.8% and 10.5% (22.9 lbs) respectively at the 36 mg dose versus 0.1% and 2.2% (5.1 lbs) with placebo.

Weight loss is somewhat lower than injectable tirzepatide (22.5% in SURMOUNT-1) or high-dose semaglutide (14.9% in STEP 1), but orforglipron represents the strongest oral GLP-1 efficacy data to date. The oral route without food or water restrictions is a meaningful adherence advantage over injectable options.

No dedicated cardiovascular outcomes trial has been completed. The NEJM ATTAIN-1 publication explicitly notes that whether the cardiovascular benefits seen with the injectable GLP-1 receptor agonist class extend to orforglipron remains to be investigated. Both ATTAIN trials showed favorable changes in surrogate cardiometabolic markers (systolic blood pressure, triglycerides, non-HDL cholesterol), but surrogate endpoints are not substitutes for hard cardiovascular outcomes.

No detailed DEXA or MRI-based lean mass versus fat mass breakdowns were reported in the primary trial publications. Waist circumference reductions were measured alongside body weight in both ATTAIN trials.

Safety is consistent with the GLP-1 class. Gastrointestinal adverse events (nausea, vomiting, constipation, diarrhea) were the most common, generally mild-to-moderate, dose-dependent, and most prominent during dose titration. Discontinuation due to adverse events was 5.3-10.3% with orforglipron versus 2.7% with placebo in ATTAIN-1. In ATTAIN-2, discontinuation was 6.1-9.9% versus 4.1% placebo. Ten deaths occurred during ATTAIN-2 (6 in orforglipron groups, 4 in placebo), with only one orforglipron-group death having any suggested treatment relationship. No pancreatitis, retinal detachment, or ischemic optic neuropathy signals were reported.

Broader GLP-1 receptor agonist class mechanisms relevant to aging biology include enhanced DNA repair (via APE1), attenuation of oxidative-stress-induced cellular senescence, reduced chronic inflammation, and improved mitochondrial function. It is unconfirmed whether orforglipron shares these effects specifically, since it has a distinct signaling bias (favoring cAMP over beta-arrestin) compared to peptide agonists.